Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any idea who’s banking $10000 to $15000 this week from IPIX?
Hopefully the CEO invested the balance of our capital.!
Nobody’s buying it!
No one is buying it and IPIX isn’t advancing it. B is dead.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170721710
IPIX is dead.
1.) the company doesn’t have financial resources to advance Brilacidin into clinical trials and 2.) the company plans to AVOID such investments of time and financial resources.
In the CEO’s own words from Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Research is still chugging along. Thank you for bringing info forward.
Maybe they think this is attractive from IPIX’s most recent 10Q -
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.”
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“
The CEO said yesterday the company is looking for additional investments with what little capital we have left and we believe him. B is dead.
Agree, nothing but dead spots under this pile of shit.
Grass is definitely not going to be growing under this investment.
The CEO clearly disposed millions of shares during the last hours of 2022 and couldn’t even enter his address correctly on the filing. This turd is toast.
LMAO. When wolves howl, sheep bleat in response.
Most recent filings show management’s plan is to spend capital on “investments” rather than clinical trials.
The CEO is banking on it.
I’ll be adding a boatload
2023 - No one is buying it.
Because no one knew in 2013 all Brilacidin could do
Among others. Isn’t that evident by the authors of the “independent” publishings?
Nope. Good guess though. He’s been poolside w/ the CEO in Boca.
Merry Christmas and blessings to all. Hope everyone has a prosperous year. As we celebrate Jesus and his birth, one must remember he also rose from the dead. Perhaps IPIX can too.
Hound.
Sounds like IPIX’s current plan is to (avoid investments of time and financial resources required for clinical trials of Brilacidin) and to (give more capital away for other investment opportunities.)
Sucks to be a bagholder at a penny. IPIX drops our investment in Kevetrin and adds lightsabers. No telling what we will be invested in next month.
Ok. A few responses, but no one supporting more capital outflow to private companies in Israel.
Any shareholders support Management’s Plan of Operation for 2023?
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
Source dated 11/10/22
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Do you support the company giving away more of our capital to private companies in Israel in 2023 for a stake in those companies?
Do you support the company giving away more of our capital to private companies in Israel in 2023?
However u’d like it phrased. Our, their, my, your. Whatever suits u. The question remains.
Any shareholders here support the company giving away more of our capital to private companies in Israel in 2023?
Also think Leo should send out an end of year update to stockholders as to why 2023 won't become just another "further investigation" year.
Of course.
Yes she does.
Lmao. Drop the mic.
I find it hilarious she has a LinkedIn page and chose not to list the name of the company she “works” for.
I made no mention of Brilacidin
“The message I got was the search for answers and solutions around Covid remains active.”
It’s clear from the preclinical studies and clinical trial that followed, along with IPIX’s current management plan, that Brilacidin isn’t the answer or solution.
I had Covid and was asymptomatic. Vaccinated. Actually enjoyed the experience. Had a ton of energy from what I suspect was increased heart rate. COVID is nothing more than the cold/flu for most at this point.
The only way I knew I had it was one person in our office had flu like symptoms so everyone tested. 4 people positive. Only 1 person had symptoms.
Based on the filings, Leo and Jane made somewhere in the neighborhood of $20k in compensation this week (and every week) thanks to all the bag holders.
Ads bring awareness. What’s not to like? New investors, please join us in our misery as our brokerage accounts approach zero.
You’re suggesting the authors are buying? LOL. The authors of this one didn’t fair so well. https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1
Here’s a common theme from the dish studies…
Competing Interest Statement
Funding: George Mason University, with identified lead researcher Aarthi Narayanan, received financial support from Innovation Pharmaceuticals Inc. to conduct research on brilacidin's antiviral properties. Conflicts of Interest: Warren Weston serves as a consultant for Innovation Pharmaceuticals Inc. Jane A. Harness is an employee of Innovation Pharmaceuticals Inc.
Same same but different. No one is buying it. https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1
And the content came from the company w/o disclaimer which goes against the info u provided. Why don’t u prove they didn’t pay for it.